Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Más filtros

Banco de datos
Tipo de estudio
Tipo del documento
Asunto de la revista
País de afiliación
Intervalo de año de publicación
1.
J Reprod Dev ; 64(1): 49-55, 2018 Feb 27.
Artículo en Inglés | MEDLINE | ID: mdl-29249781

RESUMEN

Brusatol, a quassinoid isolated from the fruit of Bruceajavanica, has recently been shown to inhibit nuclear factor erythroid 2-related factor 2 (Nrf2) via Keap1-dependent ubiquitination and proteasomal degradation or protein synthesis. Nrf2 is a transcription factor that regulates the cellular defense response. Most studies have focused on the effects of Nrf2 in tumor development. Here, the critical roles of Nrf2 in mouse early embryonic development were investigated. We found that brusatol treatment at the zygotic stage prevented the early embryo development. Most embryos stayed at the two-cell stage after 5 days of culture (P < 0.05). This effect was associated with the cell cycle arrest, as the mRNA level of CDK1 and cyclin B decreased at the two-cell stage after brusatol treatment. The embryo development potency was partially rescued by the injection of Nrf2 CRISPR activation plasmid. Thus, brusatol inhibited early embryo development by affecting Nrf2-related cell cycle transition from G2 to M phase that is dependent on cyclin B-CDK1 complex.


Asunto(s)
Ciclo Celular/efectos de los fármacos , Desarrollo Embrionario/efectos de los fármacos , Factor 2 Relacionado con NF-E2/antagonistas & inhibidores , Animales , Ciclo Celular/fisiología , Regulación hacia Abajo/efectos de los fármacos , Desarrollo Embrionario/fisiología , Femenino , Ratones , Extractos Vegetales/farmacología , Cuassinas/farmacología , Transducción de Señal/efectos de los fármacos
2.
Reprod Biomed Online ; 32(5): 538-44, 2016 May.
Artículo en Inglés | MEDLINE | ID: mdl-27020131

RESUMEN

This study aimed to elucidate the effect of electroacupuncture treatment on preventing early ovarian hyperstimulation syndrome (OHSS) and the potential mechanisms involved using an induced rat model. The ovarian response was examined by measuring ovary weight, vascular permeability, levels of inflammation (interleukin-6), tumour necrosis factor alpha, chemokine ligand 2 (also known as monocyte chemoactic protein 1), vascular endothelial growth factor and hormone concentrations (oestradiol, progesterone, testosterone and prolactin). Sprague-Dawley female rats underwent ovarian stimulation to induce OHSS. Hyperstimulated rats received consecutive electroacupuncture treatment from 3 days before the beginning of pregnant mare serum gonadotrophin treatment or the time point of pregnant mare serum gonadotrophin treatment respectively, and last until 3 days after HCG administration. Electroacupuncture treatment reduced ovary weight and vascular permeability in hyperstimulated rats. Electroacupuncture treatment also reduced the levels of serum steroid hormones (progesterone and testosterone), inflammatory cytokines (interleukin-6, tumour necrosis factor alpha and monocyte chemotactic protein 1 and vascular endothelial growth factor in hyperstimulated rats. The results indicate that electroacupuncture can modulate endocrine hormone secretion and affect the secretion of inflammatory cytokines and vascular endothelial growth factor, and thus prevent the progress of OHSS. Electroacupuncture may provide a simple and effective method for the prevention and treatment of OHSS.


Asunto(s)
Modelos Animales de Enfermedad , Electroacupuntura , Síndrome de Hiperestimulación Ovárica/prevención & control , Animales , Citocinas/sangre , Progresión de la Enfermedad , Femenino , Ovario/irrigación sanguínea , Ratas , Ratas Sprague-Dawley
3.
Zhonghua Nan Ke Xue ; 20(12): 1068-72, 2014 Dec.
Artículo en Zh | MEDLINE | ID: mdl-25597170

RESUMEN

OBJECTIVE: To investigate the protective effect of epigallocatechin gallate (EGCG) on mouse sperm in vivo. METHODS: A total of 64 six-week-old male Kuming mice were randomly divided into eight groups of equal number to be treated with normal saline (negative control), Cyclophosphamide (CP) at 30 mg/kg (positive control), and CP followed by EGCG (experimental) at 20, 40, and 80 mg/kg, respectively, given every other day for 10 days. At 4 and 5 weeks after treatment, the bilateral testes of the mice were harvested for examination of sperm abnormality. RESULTS: EGCG did not increase the rate of CP-induced sperm abnormality in the mice, but reduced it instead with the prolonged time of treatment. CONCLUSION: EGCG protects mouse sperm in vivo.


Asunto(s)
Catequina/análogos & derivados , Espermatozoides/efectos de los fármacos , Animales , Catequina/farmacología , Ciclofosfamida/toxicidad , Masculino , Ratones , Mutágenos/toxicidad , Distribución Aleatoria , Factores de Tiempo
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA